Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas S Tyler

Showing results (1-10 of 222) with videos related to

Pageof 23
Sort By:
Annals of Surgical Oncology|July 6, 2016
What is the OPTiMal Way to Manage In-Transit Disease?Kelly Olino, Douglas S Tyler
Annals of Surgical Oncology|February 26, 2016
Finish Line or Beginning? Welcome the New Board-certified Surgical OncologistsDouglas S Tyler, Fabrizio Michelassi
Annals of Surgical Oncology|December 2, 2021
Post-Publication Discussion: Invitation for ReplyMark S Roh, Douglas S Tyler,
Oncology (Williston Park, N.Y.)|February 15, 2012
Treatment of in-transit melanoma: an opportunity to discover critical knowledgeGeorgia M Beasley, Douglas S Tyler
Annals of Surgical Oncology|April 14, 2005
Nomograms and staging in melanoma: new tools for better predicting outcomesDouglas S Tyler, Charles M Balch
The Surgical Clinics of North America|March 23, 2017
Gastric NeoplasmsKelly L Olino, Douglas S Tyler
Annals of Surgical Oncology|March 19, 2011
Standardizing regional therapy: developing a consensus on optimal utilization of regional chemotherapy treatments in melanomaGeorgia M Beasley, Douglas S Tyler
Surgical Oncology Clinics of North America|September 8, 2004
Neoadjuvant therapy for pancreatic cancer: the Duke experienceRebekah R White, Douglas S Tyler
Annals of Surgical Oncology|February 4, 2009
Optimizing regional therapy for melanomaGeorgia M Beasley, Douglas S Tyler
Surgical Oncology Clinics of North America|August 30, 2008
Current clinical and research approaches to optimizing regional chemotherapy: novel strategies generated through a better understanding of drug pharmacokinetics, drug resistance, and the development of clinically relevant animal modelsGeorgia M Beasley, Lauren Kahn, Douglas S Tyler
Pageof 23

Showing results (1-10 of 222) with videos related to

Sort By:
Pageof 23
Annals of Surgical Oncology|July 6, 2016
What is the OPTiMal Way to Manage In-Transit Disease?Kelly Olino, Douglas S Tyler
Annals of Surgical Oncology|February 26, 2016
Finish Line or Beginning? Welcome the New Board-certified Surgical OncologistsDouglas S Tyler, Fabrizio Michelassi
Annals of Surgical Oncology|December 2, 2021
Post-Publication Discussion: Invitation for ReplyMark S Roh, Douglas S Tyler,
Oncology (Williston Park, N.Y.)|February 15, 2012
Treatment of in-transit melanoma: an opportunity to discover critical knowledgeGeorgia M Beasley, Douglas S Tyler
Annals of Surgical Oncology|April 14, 2005
Nomograms and staging in melanoma: new tools for better predicting outcomesDouglas S Tyler, Charles M Balch
The Surgical Clinics of North America|March 23, 2017
Gastric NeoplasmsKelly L Olino, Douglas S Tyler
Annals of Surgical Oncology|March 19, 2011
Standardizing regional therapy: developing a consensus on optimal utilization of regional chemotherapy treatments in melanomaGeorgia M Beasley, Douglas S Tyler
Surgical Oncology Clinics of North America|September 8, 2004
Neoadjuvant therapy for pancreatic cancer: the Duke experienceRebekah R White, Douglas S Tyler
Annals of Surgical Oncology|February 4, 2009
Optimizing regional therapy for melanomaGeorgia M Beasley, Douglas S Tyler
Surgical Oncology Clinics of North America|August 30, 2008
Current clinical and research approaches to optimizing regional chemotherapy: novel strategies generated through a better understanding of drug pharmacokinetics, drug resistance, and the development of clinically relevant animal modelsGeorgia M Beasley, Lauren Kahn, Douglas S Tyler
Pageof 23